MassDevice

Abbott: Study shows neuromod systems greatly reduce pain-related healthcare visits

Abbott’s neuromodulation systems can significantly reduce pain-related healthcare visits for people living with chronic pain, according to five-year data.
Pharmabiz

Five-year data shows Abbott neuromodulation systems reduce healthcare visits related to pain and deliver sustained relief

Abbott Park, Illinois Tuesday, January 27, 2026, 13:00 Hrs [IST] ...
Seeking Alpha

Abbott Receives FDA Approval for Its Spinal Cord Stimulation Systems to Treat Chronic Back Pain in People Who Have Limited Surgical Options

ABBOTT PARK, Ill., May 16, 2023 /PRNewswire/ -- Abbott announced today that the U.S. Food and Drug Administration (FDA) has approved its spinal cord stimulation (SCS) devices for the treatment of ...
Medscape

FDA Clears 'Recharge-Free' Neurostimulation Device for Chronic Pain

The US Food and Drug Administration (FDA) has approved Abbott Laboratories' Proclaim XR neurostimulation system for chronic pain patients. The device has a battery life of up to 10 years, the company ...
Law

Fuller v. Abbott Laboratories

The U.S. Food and Drug Administration and Abbott Laboratories were hit with a product liability lawsuit on Oct. 17 in Illinois Northern District Court over Abbott's Proclaim Elite spinal cord ...